Background and purpose The real-life application of DAWN and DEFUSE-3 trials has been poorly investigated. We aimed to identify the proportion of patients with acute ischemic stroke (AIS) eligible for late endovascular treatment (EVT) in our stroke center based on trial and more liberal selection criteria.
Methods All consecutive patients in our stroke registry (2003–2017) admitted within 5–23 hours of last proof of good health were selected if they had complete clinical and radiological datasets. We calculated the proportion of patients eligible for late EVT according to trial (DAWN and/or DEFUSE-3) and more liberal clinical/imaging mismatch criteria (including lower admission National Institutes of Health Stroke Scale score and Alberta Stroke Program Early CT Score for core estimation).
Results Of 1705 patients with AIS admitted to our comprehensive stroke center in the late time window, we identified 925 patients with complete clinical and radiological data. Among them, the proportions of late EVT eligibility were 2.5% (n=23) with DAWN, 5.1% (n=47) with DEFUSE-3, and 11.1% (n=103) with more liberal criteria. Considering late-arriving patients with large vessel occlusion (n=221), the percentages of eligible patients were 10.4%, 21.3%, and 46.6%, respectively. A favorable outcome was observed at comparable rates in treated patients selected by trial or liberal criteria (67% vs 58%, p=0.49).
Conclusions In a long-term stroke registry, the proportion of late EVT eligibility varied greatly according to selection criteria and referral pattern. Among late-arriving patients referred to our comprehensive stroke center, we found 5.6% eligible according to trial (DAWN/DEFUSE-3) and 11.1% according to liberal criteria. These data indicate that late EVT could be offered to a larger population of patients if more liberal criteria are applied.
- CT angiography
- CT perfusion
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors SN studied the concept and design, helped with analysis and interpretation, and prepared the article. DS, GSi and PV helped with interpretation of data and critical revision of the article for important intellectual content. MA carried out data analysis and interpretation and helped with preparation of the article. AE helped with data acquisition and analysis. VD and GSa helped with radiological data acquisition and critical revision of the article for important intellectual content. MW contributed to the conception and design and helped with the interpretation of data. PM studied the concept and design, helped with data acquisition, analysis and interpretation, critical revision of the article for important intellectual content, and study supervision.
Funding This work was supported by the Swiss National Science Foundation (grant number: 320030_182654).
Competing interests GSi: research grant from the Swiss Heart Foundation, congress travel support from Bayer and Shire and consultant for scientific advisory boards for Amgen and Daiichi-Sankyo. PV: research grants from the National Institute of Disease and Health Insurance (NIDHI/Belgium) through his institution; speaker fees from Daiichi-Sankyo, Pfizer and Alexion; honoraria from scientific advisory boards from Boehringer-Ingelheim. PM: research grants from the Swiss Heart Foundation and the Swiss National Science Foundation.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Anonymized data can be shared by request from any qualified investigator